QurAlis Corporation, a Cambridge, MA-based new private biotech company focused on developing precision solutions to cure ALS, raised a seed funding round of undisclosed amount.
Backers included MP Healthcare Venture Management (MPH), Amgen Ventures, and Alexandria Venture Investments.
The company is using the funds to advance treatments to cure Amyotrophic Lateral Sclerosis (ALS).
Founded by Harvard professors and ALS and stem cell pioneers, Dr. Kevin Eggan and Dr. Clifford Woolf, along with Jonathan Fleming, CEO of Q-State Biosciences, and QurAlis’ CEO, Dr. Kasper Roet, QurAlis is developing three precision therapies targeting three distinct subtypes of ALS: a drug to restore a dysfunctional cellular waste clearance system that progressively poisons neurons; a drug to treat overactive neurons and prevent cell death via excitotoxicity; and a transformative device to remove toxic proteins.
FinSMEs
05/04/2018